| Literature DB >> 31838943 |
Jie Sun1, Zhen Tong1, An Shi, Dong Li1, Wei Xue1, Yiran Huang1.
Abstract
Holmium laser enucleation of the prostate (HoLEP) is one of the minimally invasive procedures that is used for patients with benign prostate hyperplasia. The procedure usually requires patients to stay in the hospital 2 nights or longer. The present study evaluated the safety and feasibility of HoLEP with discharge of the patients on Day 1 after surgery (1-day surgery). A total of 1,164 patients were included in the study, with 510 of them planned for 1-day surgery and others planned for inpatient surgery. The primary outcomes included complication rate and clinical outcomes. A total 489 out of 510 patients received 1-day HoLEP and were discharged on Day 1 after surgery. In a 30-day follow-up period, no significant differences were found between the 1-day and inpatient surgery groups in terms of the rate of complications and clinical outcomes. Patients in the 1-day surgery group had a significantly shorter waiting time for admission (9.5 ± 4.8 vs. 17.6 ± 7.4 days, p < .05), and the mean hospitalization cost was lower (CNY$ 9140.6 ± 1452.2 vs. 10533.4 ± 1594, p < .05).The 1-day HoLEP surgery was safe and had satisfactory clinical outcomes. This treatment strategy could reduce the waiting time for admission and cost of hospitalization. Majority of the patients found this 1-day surgery beneficial, especially elderly patients who prefer to have an early return home and rapid resumption of activities.Entities:
Keywords: 1-day surgery; benign prostate hyperplasia; holmium laser enucleation of the prostate; lower urinary tract symptoms
Year: 2019 PMID: 31838943 PMCID: PMC6913051 DOI: 10.1177/1557988319894480
Source DB: PubMed Journal: Am J Mens Health ISSN: 1557-9883
Treatment Indications for Patients Receiving HoLEP Treatment.
Note. BPH = benign prostate hyperplasia; HoLEP = holmium laser enucleation of the prostate; LUTS = lower urinary tract symptoms.
Comparison of Baseline Clinical Characteristics and Operative Parameters Between the Two Groups.
| Inpatient surgery | One-day surgery | ||
|---|---|---|---|
| Age (years) | 71.6 ± 8.3 | 69.9 ± 8.7 | .000 |
| Size of prostate (g) | 53.4 ± 26.7 | 51.9 ± 24.7 | .326 |
| Preoperative PSA (ng/mL) | 5.7 ± 4.8 | 5.9 ± 4.5 | .468 |
| Preoperative IPSS | 28.5 ± 5.7 | 27.9 ± 5.4 | .069 |
| Preoperative Qmax (mL/s) | 7.4 ± 2.4 | 7.7 ± 2.9 | .054 |
| Preoperative PVR (mL) | 160.3 ± 54.3 | 189.5 ± 80.9 | .000 |
| Anticoagulation ( | 63 | 58 | .335 |
| Aspirin | 48 | 40 | |
| Plavix | 16 | 18 | |
| Waiting days for operation | 17.6 ± 7.4 | 9.5 ± 4.8 | .000 |
| Mean surgery time (min) | 47.9 ± 24.1 | 46.7 ± 18.2 | .350 |
| Resected weight (g) | 33.4 ± 16.8 | 34.4 ± 19.5 | .348 |
| Total hospitalization cost (¥)* | 10,533.4 ± 1,594.3 | 9,140.6 ± 1,452.2 | .000 |
Note. *The cost included cost for laboratory and imaging examination as well as fees for anesthesia, surgery, medicine, hospital accommodation, and nursing care. IPSS = International Prostate Symptom Score; PSA = prostate-specific antigen; Qmax = maximal urinary flow rate; PVR = postvoid residual.
Clinical Outcomes at 1-Month Follow-Up in the Two Groups.
| Inpatient surgery | One-day surgery | ||
|---|---|---|---|
| IPSS | 7.5 ± 4.4 | 7.3 ± 3.5 | .839 |
| Qmax (mL/s) | 17.4 ± 3.1 | 17.6 ± 3.4 | .296 |
| PVR (mL) | 24.6 ± 14.0 | 26.5 ± 11.3 | .013 |
| PSA (mL) | 2.1 ± 1.8 | 2.4 ± 2.2 | .014 |
| Incidental prostate carcinoma ( | 15 | 12 |
Note. IPSS = International Prostate Symptom Score; PSA = prostate-specific antigen; PVR = postvoid residual; Qmax = maximum urinary flow rate.
Comparison of Complications at 1-Month Follow-Up After Surgery [n (%)].
| Postoperative complications | Inpatient surgery | One-day surgery | |
|---|---|---|---|
| Clavien–Dindo grade I | 116 (17.8%) | 87 (17.1%) | .762 |
| Bleeding | 48 (7.3%) | 41(8.0%) | |
| Urinary incontinence | 27 (4.1%) | 19 (3.7%) | |
| Irritative symptoms | 75 (11.5%) | 52 (10.2%) | |
| Clavien–Dindo grade II | 46 (7.0%) | 34 (6.7%) | .806 |
| Urinary tract infection | 16 (2.4%) | 14 (2.7%) | |
| Blood transfusion | 2 (0.03%) | 0 | |
| Urinary incontinence | 8 (1.2%) | 5 (1.0%) | |
| Irritative symptoms | 10 (1.5%) | 6 (1.2%) | |
| Recatheterization | 19 (2.9%) | 12 (2.4%) | |
| Clavien–Dindo grade III–IV | 14 (2.1%) | 10 (2.0%) | .830 |
| Bleeding | 1 (0.2%) | 1(0.2%) | |
| Urinary stricture | 9 (1.4%) | 6 (1.7%) | |
| Bladder neck contracture | 4 (0.6%) | 2 (0.4%) | |
| Acute cerebral infarction | 0 | 1 (0.2%) | |
| Readmission rate | 11 | 7 | .671 |